Published in Gene Therapy Weekly, June 19th, 2003
The patent describes an AAV manufacturing process in which the growth conditions used to culture the production cells lead to the release of vector particles into the cell culture medium without the need for breaking open the host cell membrane. This approach leads to improved production quality and allows for a more cost-effective approach to large-scale manufacturing of AAV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.